Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026

Fineline Cube May 19, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients

Fineline Cube Jan 29, 2024

The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...

Company Deals Drug

Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101

Fineline Cube Jan 29, 2024

Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...

Company Drug

Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke

Fineline Cube Jan 29, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...

Company Drug

Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 29, 2024

Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...

Company Deals

Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF

Fineline Cube Jan 29, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Company Drug

Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors

Fineline Cube Jan 29, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals Drug

Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong

Fineline Cube Jan 29, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...

Company Deals

Formosa Pharmaceuticals Strikes Licensing Deal with Cristália for Ocular Surgery Pain Treatment in Brazil

Fineline Cube Jan 29, 2024

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based...

Company

Lonza Announces Factory Closures in the US and China Amid Global Network Optimization

Fineline Cube Jan 29, 2024

Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...

Company Policy / Regulatory

China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies

Fineline Cube Jan 29, 2024

A bipartisan bill introduced on January 26, 2024, by members of the US House Select...

Company Drug

Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China

Fineline Cube Jan 28, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...

Company Deals

Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center

Fineline Cube Jan 26, 2024

The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology...

Company Deals

Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories

Fineline Cube Jan 26, 2024

Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...

Company Drug

Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia

Fineline Cube Jan 26, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...

Company Drug

Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis

Fineline Cube Jan 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

MSD Partners with Variational AI to Harness Generative AI for Drug Discovery

Fineline Cube Jan 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...

Company Drug

Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin

Fineline Cube Jan 26, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Policy / Regulatory

China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care

Fineline Cube Jan 26, 2024

The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...

Company Drug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors

Fineline Cube Jan 26, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...

Company Drug

Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study

Fineline Cube Jan 26, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...

Posts pagination

1 … 409 410 411 … 667

Recent updates

  • Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production
  • Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026
  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Company Drug

Viatris Submits Fast-Acting Meloxicam NDA to FDA for Moderate-to-Severe Acute Pain; Decision Expected December 2026

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.